UBE2C and metastatic malignant neoplasm in the lymph nodes: By log rank test, we found that OSCC patients with high UBE2C level had a significantly shorter DSS, especially for those with advanced pathological stage (Figure 1B, p < 0.001) and lymph node metastasis (Figure 1C, p = 0.019).